Search results
-
- IGF1 and insulin receptor single nucleotide variants associated with response in HER2-negative breast cancer patients treated with neoadjuvant chemotherapy with or without a fasting mimicking diet (BOOG 2013-04 DIRECT trial)
-
- Phase 1 study to evaluate the safety of reducing the prophylactic dose of dexamethasone around docetaxel infusion in patients with prostate and breast cancer
-
- Accuracy of heart rate measurement by the Fitbit Charge 2 during wheelchair activities in people with spinal cord injury
-
- Evaluating the effectiveness and cost-effectiveness of seizure dogs in persons with medically refractory epilepsy in the Netherlands
-
- Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
-
- Effects of controlled ovarian stimulation on toxicity of TAC chemotherapy in early breast cancer patients
-
- Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy
-
- Insulin-like growth factor 1 receptor expression and polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial (BOOG 2010-01)
-
- Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
-
- Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia
-
- The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study